Skip to content
Research Article Open access CC BY 3.0

Thromboprophylaxis for Intensive Care Patients

Sian Robinson, Palle Toft

Journal of Advances in Medicine and Medical Research · pp. 46–56 · Published 14 Sep 2013

10.9734/BJMMR/2014/5553

Abstract

The advent of low-molecular-weight heparin (LMWH) marked a new chapter in the prevention of venous thromboembolism. The enviable pharmacokinetic properties associated with this class of medication, ensured the place of LMWH as an attractive, if albeit more expensive alternative to unfractionated heparin. Predictable and reproducible dose response continues to negate the need for monitoring in most patient groups, while the availability of antidotes further boosts the safety profile of LMWH. These agents have long proven their worth in the medico-surgical patient population. However we have recently shown in randomised studies, that LMWH at the current recommended dose may not be as effective for critically ill patients. Critically ill patients encompass that population of patients with profound disturbance of physiology, who are at imminent risk of death and in need of continuous care. Such patients have proven to be somewhat resistant, and current evidence indicates that they may benefit from a higher dose of LMWH. A difficult undertaking, considering the heterogeneity of this population, as well as their predisposition to both haemorrhage and thromboembolism. A variety of new oral antithrombotics has recently become available for use among certain patient populations, but has not yet been studied in the intensive care unit (ICU) setting. These agents have been associated with increased risk of bleeding, and as yet, a definitive strategy in the event of major bleeding does not exist. In addition, they are more costly when compared with LMWH. All the aforementioned factors combine to make the new oral agents, unattractive alternatives for thromboprophylaxis in the ICU population.

Heparin intensive care thromboprophylaxis venous thromboembolism low-molecular-weight heparin mechanical thromboprophylaxis rivaroxaban dabigatran

References (40)

  1. 1 Surviving Sepsis Campaign [DOI]
  2. 2 Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012 [DOI]
  3. 3 Prevention of Venous Thromboembolism [DOI]
  4. 4 Prevention of Venous Thromboembolism [DOI]
  5. 5 Prevention of VTE in Nonsurgical Patients [DOI]
  6. 6 Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty [DOI]
  7. 7 Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty [DOI]
  8. 8 Heparin and Low-Molecular-Weight Heparin [DOI]
  9. 9 Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients [DOI]
  10. 10 Deep Vein Thrombosis and Its Prevention in Critically Ill Adults [DOI]
  11. 11 Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients [DOI]
  12. 12 Dalteparin versus Unfractionated Heparin in Critically Ill Patients [DOI]
  13. 13 Deep venous thrombosis in medical-surgical critically ill patients: Prevalence, incidence, and risk factors [DOI]
  14. 14 Nadroparin in the Prevention of Deep Vein Thrombosis in Acute Decompensated COPD [DOI]
  15. 15 Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors [DOI]
  16. 16 Low-Molecular-Weight Heparin and Mortality in Acutely Ill Medical Patients [DOI]
  17. 17 Heparin and low-molecular weight heparins [DOI]
  18. 18 Omission of Early Thromboprophylaxis and Mortality in Critically Ill Patients [DOI]
  19. 19 Low-Molecular-Weight Heparin [DOI]
  20. 20 The Relationship between Anti-Factor Xa Level and Clinical Outcome in Patients Receiving Enoxaparine Low Molecular Weight Heparin to Prevent Deep Vein Thrombosis after Hip Replacement [DOI]
  21. 21 Mechanisms responsible for the failure of protamine to inactivate low‐molecular‐weight heparin [DOI]
  22. 22 Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?* [DOI]
  23. 23 Bleeding during critical illness: A prospective cohort study using a new measurement tool [DOI]
  24. 24 Dosing and Monitoring of Low‐Molecular‐Weight Heparins in Special Populations [DOI]
  25. 25 Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin [DOI]
  26. 26 Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors [DOI]
  27. 27 Mechanical Thromboprophylaxis in Critically Ill Patients: A Systematic Review and Meta-Analysis [DOI]
  28. 28 Venous thromboembolism in critically ill patients [DOI]
  29. 29 Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency [DOI]
  30. 30 Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial [DOI]
  31. 31 Thromboprophylaxis in the intensive care unit: Focus on medical–surgical patients [DOI]
  32. 32 A comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: a double-blinded, randomised controlled trial [DOI]
  33. 33 Challenges in Variation and Responsiveness of Unfractionated Heparin [DOI]
  34. 34 Low-molecular-weight or Unfractionated Heparin in Venous Thromboembolism: The Influence of Renal Function [DOI]
  35. 35 Low molecular weight heparin and bleeding in patients with chronic renal failure [DOI]
  36. 36 Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery [DOI]
  37. 37 Pulmonary embolism in mechanically ventilated patients requiring computed tomography [DOI]
  38. 38 Enoxaparin [DOI]
  39. 39 Safety and efficacy of low-molecular-weight heparins in prophylaxis of deep vein thrombosis in postoperative/ICU patients: A comparative study [DOI]
  40. 40 Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism [DOI]

Cited by 2

Prophylaxis and incidence of symptomatic deep vein thrombosis in indian patients with sepsis: DETECT-deep vein thrombosis registry

DETECT-DVT Investigators · Indian Journal of Critical Care Medicine · 2017

Showing 1 of 2 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

35

Page views

0

PDF downloads

5

Outbound clicks

2

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.